| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
Purity: =98.70%
| Targets |
Natural flavone
Cirsilineol selectively targets the IFN-γ/STAT1/T-bet signaling pathway in intestinal CD4+ T cells. By inhibiting this pathway, it suppresses the differentiation and function of Th1 cells, which play a critical role in the pathogenesis of inflammatory bowel disease and other T cell-mediated inflammatory conditions. The compound's immunosuppressive effects are mediated through the downregulation of STAT1 phosphorylation and T-bet expression. It also exhibits anticancer activity by inducing apoptosis in cancer cells. |
|---|---|
| ln Vitro |
In a dose-dependent manner, cirsilineol (0.1-10 μM; 96) suppresses Concanava A-induced T cell proliferation as well as single mixed hour responses. T's activity is unaffected by cirsilineol (10 μM). IFN-γ-induced Tyr701 phosphorylated STAT1 and JAK2 activation is totally inhibited by Cirsilineol (10 μM) compared to T Cirsilineol (1–10 μM; inhibition for 3 hours) [1].Cytotoxic activity is not the cause of the reduction of cell proliferation[1].
Cirsilineol (0.1-10 μM; 96 hours) inhibits the single mixed lymphocyte reaction and Concanavalin A-induced T-cell proliferation in a dose-dependent manner. At 10 μM, it does not affect T lymphocyte viability, indicating that its antiproliferative effect is not due to cytotoxicity. The compound's immunosuppressive activity is selective for T cells, with minimal effects on other immune cell populations. It also exhibits anti-proliferative activity against various cancer cell lines. |
| ln Vivo |
By blocking IFN-γ/STAT1/T-bet signaling in CD4+ T cells, cirsilineol (3, 10, and 30 mg/kg) dramatically reduced TNBS-induced Th1-mediated cardiovascular inflammation.
In vivo, cirsilineol significantly ameliorates TNBS-induced T cell-mediated experimental colitis in mice. This effect is attributed to its immunosuppressive activity and inhibition of IFN-γ/STAT1/T-bet signaling in intestinal CD4+ T cells. The compound has also been studied for its anticancer properties in animal models, although detailed data are limited. Its oral bioavailability and in vivo efficacy make it a promising candidate for the treatment of inflammatory bowel disease and other T cell-mediated disorders. |
| Enzyme Assay |
In vitro assays for cirsilineol typically involve T cell proliferation assays. Mouse or human T cells are stimulated with Concanavalin A or in a mixed lymphocyte reaction. Cells are treated with cirsilineol at concentrations ranging from 0.1 to 10 μM for 96 hours. Proliferation is measured by [3H]-thymidine incorporation or by CFSE dilution. Cytotoxicity is assessed using trypan blue exclusion or LDH release assays. STAT1 phosphorylation and T-bet expression are measured by Western blotting or flow cytometry.
|
| Cell Assay |
Cell Proliferation Assay[1] Inhibition of cell proliferation is not due to cytotoxic activity[1].
Cell Types: Splenocytes Tested Concentrations: 0.1, 1, 10 μM Incubation Duration: 96 hrs (hours) Experimental Results: Inhibition of single mixed lymphocyte reaction and concanavalin A (Con A; 5 μg/mL; for 72 hrs (hours)) induction in a dose-dependent manner of T cell proliferation. Inhibits the proliferation of OVA323-339-specific CD4+ T cells. Western Blot Analysis[1] Cell Types: Splenic CD4+ T cells Tested Concentrations: 1, 5, 10 μM Incubation Duration: 3 hrs (hours) of pretreatment Experimental Results: Complete inhibition of IFN-γ-induced (25 ng; 30 minutes) Tyr701 phosphorylation of STAT1 and JAK2 activation. Inhibits IFN-γ induction (25 ng; 12 hrs (hours)) of the Th1-specific transcription factor T-bet. Cellular assays for cirsilineol are performed using primary CD4+ T cells or T cell lines. Cells are treated with cirsilineol at various concentrations (typically 0.1-10 μM) for 24-96 hours. The expression of IFN-γ, STAT1, and T-bet is measured by qRT-PCR, Western blotting, or flow cytometry. Cytokine secretion is quantified by ELISA. Apoptosis is assessed by Annexin V staining or caspase activity assays in cancer cell lines. |
| Animal Protocol |
Animal/Disease Models: 8-10 weeks old female C57BL/6, BALB/c and DO11.10 transgenic mice using TNBS (10 mg; 100 μL) [1]
Doses: 3, 10, 30 mg/kg Route of Administration: IP; daily; 11 days Experimental Results: Dramatically improved the body weight and survival rate of mice. Dramatically reduces inflammatory infiltration, restores destructive mucosal structure and relieves edema. In vivo studies with cirsilineol are conducted in mouse models of T cell-mediated colitis, such as the TNBS-induced colitis model. Female C57BL/6, BALB/c, or DO11.10 transgenic mice are treated with TNBS intrarectally to induce colitis. Cirsilineol is administered orally or intraperitoneally at doses of 10 and 30 mg/kg. Disease severity is assessed by measuring body weight, stool consistency, and histological scoring of colonic inflammation. Inflammatory cytokine levels are measured in colonic tissue homogenates. |
| ADME/Pharmacokinetics |
Pharmacokinetic data for cirsilineol are limited, as it is a natural product research compound. Its oral bioavailability and metabolic stability have not been extensively characterized. The compound's molecular weight is 344.36 g/mol. For in vivo studies, it is typically formulated in suitable vehicles such as carboxymethylcellulose or DMSO/PEG mixtures. Its lipophilic nature suggests moderate membrane permeability, but detailed ADME data are not available.
|
| Toxicity/Toxicokinetics |
Toxicological data for cirsilineol are limited. In cell-based assays, the compound does not affect T lymphocyte viability at concentrations up to 10 μM. No significant adverse effects have been reported in animal studies at the doses used for colitis treatment. However, comprehensive toxicological evaluation, including acute and chronic toxicity studies, has not been performed. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
Cirsilineol is a trimethoxyflavonoid with a flavonoid structure in which methoxy groups are substituted at the 6, 7, and 3' positions, and hydroxy groups are substituted at the 5 and 4' positions. It is a plant metabolite and an antitumor agent. It is both a trimethoxyflavonoid and a dihydroxyflavonoid. Its function is related to that of flavonoid compounds. Cirsilineol has been reported in Ajania fastigiata, Salvia officinalis, and other organisms with relevant data. See also: Orange peel (partial).
Cirsilineol is a natural flavonoid with immunosuppressive and anticancer properties. It is being investigated as a potential therapeutic agent for T cell-mediated inflammatory diseases, such as inflammatory bowel disease. The compound is also studied for its anti-proliferative activity against cancer cells. It is not approved for clinical use and is intended for laboratory research only. Ongoing research continues to explore its mechanism of action and therapeutic potential. |
| Molecular Formula |
C18H16O7
|
|---|---|
| Molecular Weight |
344.3154
|
| Exact Mass |
344.09
|
| Elemental Analysis |
C, 62.79; H, 4.68; O, 32.53
|
| CAS # |
41365-32-6
|
| PubChem CID |
162464
|
| Appearance |
Typically exists as White to light yellow solids at room temperature
|
| Density |
1.387g/cm3
|
| Boiling Point |
585ºC at 760 mmHg
|
| Flash Point |
215.2ºC
|
| Index of Refraction |
1.627
|
| LogP |
2.897
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
520
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(=C([H])C(C2=C(C(=C(C([H])=C12)OC([H])([H])[H])OC([H])([H])[H])O[H])=O)C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])O[H]
|
| InChi Key |
VKOSQMWSWLZQPA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O7/c1-22-13-6-9(4-5-10(13)19)12-7-11(20)16-14(25-12)8-15(23-2)18(24-3)17(16)21/h4-8,19,21H,1-3H3
|
| Chemical Name |
5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-6,7-dimethoxychromen-4-one
|
| Synonyms |
Eupatrin; Fastigenin; Anisomelin; 4',5-Dihydroxy-3',6,7-trimethoxyflavone; Cirsileneol; 4,5-Dihydroxy-3,6,7-trimethoxyflavone;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA